申请人:Kabi Pharmacia Aktiebolag
公开号:US05236956A1
公开(公告)日:1993-08-17
The invention concerns compounds having the formula I ##STR1## wherein Ar is a phenyl or benzyl group which is optionally substituted with hydroxy or alkoxy; R.sup.1 is hydrogen, lower alkyl, lower alkoxy, hydroxy; R.sup.2 is hydrogen, lower alkyl; R.sup.3 is NR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 which can be the same or different, are lower alkyl, or wherein R.sup.4 and R.sup.5, when taken together, form a ring with the nitrogen atom, whereby said ring optionally is substituted with lower alkyl; n is 0 or 1; m is 2 or 3 and their salts with physiologically acceptable acids and when the compounds can be in form of optical isomers, the racemic mixture and the individual isomers, for the treatment of disorders of the urinary bladder.
该发明涉及具有以下式I的化合物
其中Ar是苯基或苄基,可以选择地用羟基或烷氧基取代;R1是氢、低烷基、低烷氧基、羟基;R2是氢、低烷基;R3是NR4R5,其中R4和R5可以相同也可以不同,为低烷基,或者当R4和R5一起时,与氮原子形成一个环,所述环可以选择地用低烷基取代;n为0或1;m为2或3以及它们与生理上可接受的酸盐,当化合物可以为光学异构体时,为治疗尿道膀胱疾病的消光体混合物和各个异构体。